SML3997
FOY-251 mesylate
≥98% (HPLC)
别名:
4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]-benzeneacetic acid, methanesulfonate; 4-(4-Guanidinobenzoyloxy)phenylacetic acid, methanesulfonate, CC6 mesylate salt, Camostat active metabolite, FOY 251 mesylate salt, FOY 305 active metabolite, FOY-305 active metabolite, FOY251 mesylate salt, GBPA mesylate salt
登录查看公司和协议定价
所有图片(1)
About This Item
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear (warmed)
儲存溫度
2-8°C
SMILES 字串
O=C(C1=CC=C(NC(N)=N)C=C1)OC2=CC=C(CC(O)=O)C=C2.O=S(O)(C)=O
生化/生理作用
Trypsin-like serine protease inhibitor Camostat (FOY-305) active metabolite with inhibitory potency against transmembrane serine protease 2 (TMPRSS2).
FOY-251 is a trypsin-like serine protease inhibitor and an active metabolite of the oral drug Camostat/FOY-305 (trypsin IC50 = 51/55 nM by FOY-305/FOY-251; plasma kallikrein/plasmin IC50 = 1.48/2.64 μM by FOY-305 and 2.32/12.5 μM by FOY-251). FOY-251 and FOY-305 are also potent inhibitor against transmembrane serine protease 2 (TMPRSS2 IC50 = 6.2/33.3 nM by by FOY-305/FOY-251) that primes SARS-CoV-2 spike protein for host cell entry.
FOY-251 is a trypsin-like serine protease inhibitor and an active metabolite of the oral drug Camostat/FOY-305 (trypsin IC50 = 51/55 nM by FOY-305/FOY-251; plasma kallikrein/plasmin IC50 = 1.48/2.64 μM by FOY-305 and 2.32/12.5 μM by FOY-251). FOY-251 and FOY-305 are also potent inhibitor against transmembrane serine protease 2 (TMPRSS2 IC50 = 6.2/33.3 nM by by FOY-305/FOY-251) that primes SARS-CoV-2 spike protein for host cell entry.
注意
Hygroscopic
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Skin Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
EBioMedicine, 65, 103255-103255 (2021)
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
Communications biology, 5(1), 681-681 (2022)
New orally active serine protease inhibitors
Journal of medicinal chemistry, 38(14), 2521-2523 (1995)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门